Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting
Hematological Oncology · 2024
DOI: 10.1002/hon.3306 ↗Kurz gefasst
Leserbrief in der Zeitschrift Hematological Oncology, 2024. Verfasst von Taku Kikuchi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Multiple Myeloma, Dexamethasone, Antineoplastic Combined Chemotherapy Protocols, Oligopeptides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
- Department of Pharmacy, Japanese Red Cross Medical Center, Tokyo, Japan.
ORCID-Profile: Taku Kikuchi
Zitieren
APA
Kikuchi, T., Tsukada, N., Kunisada, K., Matsumoto, C., Nomura-Yogo, M., Oda, Y., Sato, K., Takei, T., Ogura, M., Abe, Y., Suzuki, K., Hosoya, O., & Ishida, T. (2024). Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting. Hematological Oncology. https://doi.org/10.1002/hon.3306
Vancouver
Kikuchi T, Tsukada N, Kunisada K, Matsumoto C, Nomura-Yogo M, Oda Y, et al. Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting. Hematological Oncology. 2024. doi:10.1002/hon.3306
BibTeX
@article{Kikuchi2024,
author = {Kikuchi, Taku and Tsukada, Nobuhiro and Kunisada, Kodai and Matsumoto, Chiaki and Nomura-Yogo, Moe and Oda, Yuki and Sato, Kota and Takei, Tomomi and Ogura, Mizuki and Abe, Yu and Suzuki, Kenshi and Hosoya, Osamu and Ishida, Tadao},
title = {Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting},
journal = {Hematological Oncology},
year = {2024},
doi = {10.1002/hon.3306}
}
EUVIMED